NCT00224393 2023-05-30
Phase II Trial of Enbrel in Patients With Primary Systemic Amyloidosis
The Cleveland Clinic
Phase 2 Completed
Clinical Trials
12 trialsNCT00031551 2017-12-06
Evaluation of Efficacy and Mechanisms of an Antiinflammatory Intervention for Chemotherapy Related Mucosal Injury
National Institutes of Health Clinical Center (CC)
Phase 2 Terminated
NCT00309907 2017-09-29
Etanercept in Treating Young Patients With Idiopathic Pneumonia Syndrome After Undergoing a Donor Stem Cell Transplant
Children's Oncology Group
Phase 2 Completed
NCT00001893 2017-07-02
Study of TNFR:Fc (Enbrel) in the Treatment of Asthma
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT00141726 2015-12-03
Study of Enbrel (Etanercept) for the Treatment Sub-Acute Pulmonary Dysfunction After Allogeneic Stem Cell Transplant
University of Michigan Rogel Cancer Center
Phase 2 Completed
NCT01730495 2015-12-02
Tumor Necrosis Factor-alpha Inhibition Using Etanercept in Chronic Fatigue Syndrome
Haukeland University Hospital
Phase 2 Terminated
NCT00509600 2012-08-07
Etanercept (Enbrel) for Juvenile Myelomonocytic Leukemia
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT00217386 2010-09-15
Anti-Thymocyte Globulin and Etanercept in Treating Patients With Myelodysplastic Syndromes
Fred Hutchinson Cancer Center
Phase 2 Completed
NCT00005853 2010-04-02
Biological Therapy in Treating Patients With Myelodysplastic Syndrome
Fred Hutchinson Cancer Center
Phase 2 Completed
NCT00141791 2009-08-07
Study Evaluating Etanercept in Moderate to Severe Asthma
Wyeth is now a wholly owned subsidiary of Pfizer
Phase 2 Completed
NCT00001901 2008-03-04
Etanercept to Treat Wegener's Granulomatosis
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT00001955 2008-03-04
Study of Etanercept and Celecoxib to Treat Temporomandibular Disorders (Painful Joint Conditions)
National Institutes of Health Clinical Center (CC)
Phase 2 Completed